Satellite Symposia - Sponsored by Servier
The Satellite Symposia are industry-sponsored programs offered in conjunction with ASH specialty meetings. These events are offered in conjunction with the 2025 Highlights of ASH in Latin America and are not part of the official ASH meeting programming and are planned solely by the sponsoring company. There is no fee to attend and registration to Highlights of ASH is not required to participate.
HOST A SATELLITE SYMPOSIUM
To host a Satellite Symposium contact Marina Bezerra at [email protected] or Virginia da Costa at [email protected]
The 2025 Satellite Symposia are each presented in-person one time, at the date, time and location listed. For program-specific questions, please reach out to the managing company contact listed below each session.
Satellite Symposia are Open to All Attendees Free of Charge. No registration is Required. Continue to Check this page as sessions are added.
Targeted Therapy in Unfit Patients With De Novo AML: The Value of Waiting for a Precise Decision
DATE: Friday, April 25
TIME: 12:15 am - 1:00 pm
Location : Auditorium 4, Punta del Este Convention Center
How to test for IDH1 Mutations in AML?
Peter J.M Valk, PhD (Speaker)
Associate Professor/ Head Hemato-oncology Laboratory
Erasmus University Medical Center, Rotterdam
The Netherlands
Exploring Treatment Options for the Unfit IDH1 Mutated AML Patient
Maria Marta Rivas, MD (Speaker)
Austral University Hospital
Buenos Aires, BA (Argentina)
Join this special session to gain valuable clinical insights alongside international experts.
Spanish:
Simposio Satélite – Patrocinado por Servier
Fecha: Viernes, 25 de abril
Horario: 12:15 a 13:00
Lugar: Auditorio 4, Punta del Este Convention Center
Tema:
Terapia dirigida en pacientes no aptos con LMA de novo: el valor de esperar para una decisión precisa
¿Cómo detectar mutaciones de IDH1 en LMA?
Peter J.M. Valk, PhD (Ponente)
Profesor Asociado / Jefe del Laboratorio de Hemato-oncología
Erasmus University Medical Center, Róterdam
Países Bajos
Explorando opciones de tratamiento para pacientes no aptos con LMA y mutación en IDH1
Dra. María Marta Rivas (Ponente)
Hospital Universitario Austral
Buenos Aires, BA (Argentina)
Participe en esta sesión especial para obtener valiosas perspectivas clínicas junto a expertos internacionales.